Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the International Operations category.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharmaceuticals faces material execution risk in scaling its global footprint to match its Alnylam 2030 ambitions, particularly as it commercializes AMVUTTRA in ATTR-CM and broadens its pipeline. The rapid expansion of headcount and geographies strains existing infrastructure, and any delay or shortfall in building operational, regulatory, and commercial capabilities, or in enhancing control systems, could impair growth and disrupt global product launches.
The average ALNY stock price target is $474.00, implying 53.66% upside potential.
To learn more about Alnylam Pharmaceuticals’ risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.